Search Results
Jun 22, 2026, 14:14 ET Phanes Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Spevatamig in Combination with Chemotherapy for the Frontline Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
rising. Thus, novel approaches capable of producing more durable responses are urgently needed. Although immunotherapies such as agents targeting PD-1/PD-L1 or CTLA-4 have been explored in many PDAC trials, few have demonstrated meaningful therapeutic benefit."Spevatamig was discovered in our
More news about: Phanes Therapeutics, Inc.
Jun 22, 2026, 09:06 ET 蘆康沙妥珠單抗聯合奧希替尼一線治療EGFR突變NSCLC轉化研究成果刊發於《Cancer Cell》
肺癌適應症領域獲批上市的TROP2 ADC藥物。sac-TMT的新增適應症上市申請已獲NMPA受理，用於聯合帕博利珠單抗（可瑞達®[1]）一線治療腫瘤細胞程序性死亡配體1(PD-L1)腫瘤細胞陽性比例評分(TPS)≥1%、EGFR陰性/間變性淋巴瘤激酶(ALK)陰性的局部晚期或轉移性NSCLC，並進入優先審評審批通道。截至當前，科倫博泰已在中國啟動9項注冊臨床研究。默沙東正在全球開展17項III期臨床研究，評估sac-TMT單藥或聯合帕博利珠單抗或其他抗癌藥物用於多種類型癌症的治療。這些研究均由默沙東發起並牽頭。關於科倫博泰
More news about: 科倫博泰
Jun 22, 2026, 09:00 ET Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa® Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer
issued a Notice of Allowance to Genprex for a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with either PD-1 or PD-L1 antibodies for the treatment of both non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
More news about: Genprex, Inc.
Jun 22, 2026, 07:42 ET 科濟藥業全球首款治療實體瘤的CAR-T細胞治療產品愷力美®獲批上市
Observatory.[3] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.
More news about: 科濟藥業
Jun 22, 2026, 07:20 ET CARsgen Announces Approval of Satri-cel, the World's First CAR T-Cell Therapy Product for Solid Tumors
Observatory.[3] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32.
More news about: CARsgen Therapeutics
Jun 22, 2026, 01:45 ET Translational Research Results of Sacituzumab Tirumotecan (sac-TMT) in Combination with Osimertinib as First-Line Treatment for EGFR-Mutant NSCLC Published in Cancer Cell
pembrolizumab (KEYTRUDA®[1]) as first‑line treatment for locally advanced or metastatic NSCLC who have programmed death ligand 1 (PD-L1) tumor proportion score (TPS)≥1% and are EGFR-negative and anaplastic lymphoma kinase (ALK)-negative has been accepted for review by the NMPA, and has
More news about: Kelun-Biotech
Jun 22, 2026, 00:00 ET Beelink 2026 Amazon Prime Day Mega Sale - Up to 20% Off
laptops with storage expansion and additional connectivity. Mate mini is tailor-made for Apple Mac mini, while Mate Pro, which adds features including 96W PD charging, voice communication, and a built-in Bluetooth speaker, is designed for laptop users.From everyday productivity and home entertainment
More news about: BEELINK
Jun 22, 2026, 00:00 ET Beelink 2026 Amazon Prime Day Mega Sale - Up to 20% Off
laptops with storage expansion and additional connectivity. Mate mini is tailor-made for Apple Mac mini, while Mate Pro, which adds features including 96W PD charging, voice communication, and a built-in Bluetooth speaker, is designed for laptop users.From everyday productivity and home entertainment
More news about: BEELINK
Jun 21, 2026, 20:30 ET Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using
More news about: Antengene Corporation Limited
Jun 19, 2026, 09:00 ET Fapon Biopharma and MOTE Therapeutics to Present Dual-Platform B-Cell Immunotherapy Franchise at BIO 2026
a robust pipeline spanning discovery, preclinical and clinical stages. Leading the clinical-stage pipeline is FP008, a global first-in-class PD1×IL10M fusion protein for immuno-oncology, currently in Phase I development with key readout anticipated in 2026. FP012 is a global first-in-class TL1A×IL10MM
More news about: Fapon Biopharma
Jun 19, 2026, 07:51 ET Zoomlion destaca a IA, a tecnologia sustentável e as prioridades globais de P&D na Sétima Conferência de Inovação Tecnológica
multimedia:https://www.prnewswire.com/br/comunicados-para-a-imprensa/zoomlion-destaca-a-ia-a-tecnologia-sustentavel-e-as-prioridades-globais-de-pd-na-setima-conferencia-de-inovacao-tecnologica-302805358.htmlFONTE
More news about: Zoomlion
Jun 18, 2026, 11:00 ET Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
patients with cervical cancer, with particularly notable survival benefits observed in immunotherapy-pretreated patients. The combination of 9MW2821 with a PD-1 inhibitor showed encouraging antitumor activity in advanced cervical cancer.Oral Presentation: BFv in Recurrent or
More news about: Mabwell
Jun 18, 2026, 08:30 ET Lancet Neurology study confirms staged bilateral focused ultrasound delivers substantial, durable relief for Parkinson's disease
company dedicated to using MR-guided focused ultrasound (MRgFUS) to transform patient care, today announced the publication of pivotal Parkinson's disease (PD) clinical trial results in The
More news about: INSIGHTEC
Jun 18, 2026, 08:30 ET Lancet Neurology study confirms staged bilateral focused ultrasound delivers substantial, durable relief for Parkinson's disease
company dedicated to using MR-guided focused ultrasound (MRgFUS) to transform patient care, today announced the publication of pivotal Parkinson's disease (PD) clinical trial results in The
More news about: Insightec
Jun 18, 2026, 07:00 ET Compugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
evaluating COM701 as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from the COM902 program, is being developed by AstraZeneca pursuant to an exclusive license
More news about: Compugen Ltd.
Jun 17, 2026, 09:00 ET Insilico Completes First-in-Human Dosing in Phase I Clinical Study of AI-Driven NLRP3 Inhibitor ISM8969, Achieving First Clinical Milestone in Collaboration with Hygtia Therapeutics
ascending dose (SAD) and multiple ascending dose (MAD) cohorts, will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered ISM8969 in healthy participants and in obese adult participants at risk of cardiovascular disease. The Phase I study is conducted
More news about: Insilico Medicine
Jun 17, 2026, 08:01 ET Nectin Therapeutics Reports Encouraging Phase 1 Results for NTX1088 in Combination with Keytruda® (pembrolizumab) at ASCO 2026
Phase 1a/1b clinical data of NTX1088 in combination with pembrolizumab (Keytruda®), Merck's (known as MSD outside of the U.S. and Canada) anti-PD1 therapy, during an oral presentation at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The data highlighted
More news about: Nectin Therapeutics, LTD.
Jun 16, 2026, 12:45 ET C'est le moment idéal pour faire des économies : Aurzen dévoile ses offres pour l'Amazon Prime Day 2026
mise au point automatique ToF instantanée et une flexibilité de rotation de 180 degrés, du sol au plafond. Les deux modèles sont équipés d'un port USB-C PD de 65 W permettant de les alimenter à l'aide d'un chargeur d'ordinateur portable ou d'une batterie externe pour une utilisation hors réseau. Pour une
More news about: Aurzen Official
Jun 16, 2026, 10:47 ET Ihr idealer Zeitpunkt zum Sparen: Aurzen präsentiert seine Angebote für den Amazon Prime Day 2026
1080p-Schärfe, Dolby Audio, sofortigem ToF-Autofokus und einer flexiblen 180-Grad-Drehbarkeit von der Wand bis zur Decke. Beide verfügen über einen 65-W-USB-C-PD-Anschluss, um über Laptop-Ladegeräte oder Powerbanks für den netzunabhängigen Betrieb betrieben zu werden. Für das ultimative mobile Setup lassen sie
More news about: Aurzen Official
Jun 16, 2026, 10:01 ET PD-L1 Biomarker Testing Market to Reach USD 1,830.7 Million by 2036 as Precision Oncology and Immunotherapy Adoption Accelerate Global Demand
immunohistochemistry (IHC), PCR-based diagnostics, and next-generation sequencing (NGS) are enabling faster and more accurate assessment of PD-L1 expression levels.PD-L1 assays are becoming critical for selecting patients eligible for immune checkpoint inhibitors, particularly in oncology indications
More news about: Future Market Insights
Jun 16, 2026, 09:00 ET Your Prime Moment to Save: Aurzen Unveils Amazon Prime Day 2026 Deals
design with native 1080p clarity, Dolby Audio, instant ToF auto focus, and 180-degree wall-to-ceiling rotation flexibility. Both feature a 65W USB-C PD port to run off laptop chargers or power banks for off-grid viewing. For the ultimate mobile setup, they can be perfectly upgraded with the cordless
More news about: Aurzen Official
Jun 16, 2026, 09:00 ET Your Prime Moment to Save: Aurzen Unveils Amazon Prime Day 2026 Deals
design with native 1080p clarity, Dolby Audio, instant ToF auto focus, and 180-degree wall-to-ceiling rotation flexibility. Both feature a 65W USB-C PD port to run off laptop chargers or power banks for off-grid viewing. For the ultimate mobile setup, they can be perfectly upgraded with the cordless
More news about: Aurzen Official
Jun 16, 2026, 08:00 ET ProJenX Announces a Development Update for Prosetin, a First-in-Class, CNS-Penetrant MAP4K Inhibitor
of prosetin at the two highest dose levels (0.70 and 1.05 mg/kg/day) achieved the target therapeutic exposure dose range established by preclinical PK/PD models.Prosetin treatment is correlated with a statistically significant, exposure-related decrease in phosphorylated MAP2K4 (pMAP2K4) in peripheral
More news about: ProJenX
Jun 16, 2026, 08:00 ET 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy
breakthroughs. In the field of tumor immunology, the inaugural Tang Prize laureates, Drs. James P. Allison and Tasuku Honjo, respectively identified CTLA-4 and PD-1 as key inhibitory immune checkpoints, paving the way for the development of antibody drugs known as immune checkpoint inhibitors and bringing major
More news about: The Tang Prize Foundation
Jun 15, 2026, 14:26 ET PTX METALS REPORTS STRONG INITIAL METALLURGICAL RESULTS AT W2 COPPER-NICKEL-PGE PROJECT
constructed from higher-grade drill core intervals sampled from several zones within the project. The sample had a head grade of 0.78% Cu, 0.32% Ni, 0.29 g/t Pd, 0.11 g/t Pt, and 0.04 g/t Au. Mineralogical characterization by QEMSCAN shows that there is approximately 3% chalcopyrite in the sample, that is well
More news about: PTX Metals Inc